Company Encyclopedia
View More
name
Ikena Oncology
IKNA.US
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
4.362 T
IKNA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ImageneBio reports Q3 cash position of $142.6 million and increased R&D expenses

    ImageneBio Inc. reported a Q3 cash position of $142.6 million, significantly up from $12.1 million at the end of 2024, following its merger with Ikena Oncology and a $75 million private placement. R&D expenses rose to $15.6 million, while general and administrative expenses increased to $11 million. The net loss for the quarter was $24.8 million, compared to $3.2 million in the previous year, largely due to merger-related costs. The company also announced protocol amendments for its Phase 2b ADAPTIVE study and upcoming data presentations.

    Reuters·
    US
    IMA
    -0.56%
    US
    IKNA
    0.00%
    Reuters·
    US
    IMA
    -0.56%
    US
    IKNA
    0.00%

    William Blair Estimates Ikena Oncology FY2029 Earnings

    William Blair analysts have projected Ikena Oncology's FY2029 earnings per share (EPS) at ($5.41), significantly lower than the current consensus estimate of ($0.91). Additionally, Wedbush has reduced its price target for Ikena Oncology from $25.00 to $23.00, maintaining a "neutral" rating. The stock opened at $17.90, with a market cap of $71.96 million. Recent insider transactions include significant share purchases by Directors David P. Bonita and Otello Stampacchia, increasing their holdings substantially.

    Market Beat·
    US
    IKNA
    0.00%
    Market Beat·
    US
    IKNA
    0.00%

    Chuangxiang Biotechnology announced the completion of the reverse merger transaction with Ikena Oncology

    On July 28, Chuangxiang Biotechnology announced the completion of a reverse merger with Ikena Oncology. After the merger, the company was renamed ImageneBio, Inc. and plans to be listed on NASDAQ on July 28, 2025, with the stock code "IMA." Imagene's core asset is the OX40-targeted monoclonal antibody IMG-007, which is currently undergoing a Phase 2b clinical trial. Following this strategic upgrade, Miragene will operate independently, and the product pipeline and resources of the original Inmagene will be transferred to Miragene

    Zhitong·
    US
    IKNA
    0.00%
    Zhitong·
    US
    IKNA
    0.00%

    Ikena Oncology (NASDAQ:IKNA) Issues Earnings Results

    Ikena Oncology (NASDAQ:IKNA) reported quarterly earnings of ($0.06) EPS, surpassing the consensus estimate of ($0.14) by $0.08. The stock rose 4.4% to $1.43 following the announcement. Goldman Sachs increased its stake in the company by 62.4%, and Wedbush lowered its price target from $25.00 to $23.00, maintaining a "neutral" rating. Ikena's stock is set for a 1-12 reverse split on July 28th. Hedge funds own 75% of the company's shares, reflecting strong institutional interest.

    Market Beat·
    US
    IKNA
    0.00%
    US
    IMA
    -0.56%
    Market Beat·
    US
    IKNA
    0.00%
    US
    IMA
    -0.56%

    Ikena Oncology Completes $75 Million Private Placement Amid Merger with Inmagene Biopharmaceuticals

    Ikena Oncology Inc. has completed a $75 million private placement following its merger with Inmagene Biopharmaceuticals. The funding involved participation from various investors, including Deep Track Capital and Foresite Capital, and will support the newly formed company, ImageneBio, Inc. ImageneBio is set to begin trading on Nasdaq under the ticker symbol "IMA" on July 28, 2025.

    Reuters·
    US
    IKNA
    0.00%
    US
    IMA
    -0.56%
    Reuters·
    US
    IKNA
    0.00%
    US
    IMA
    -0.56%